Staph Bacteria Metabolic Redundancy Study
Table of Contents
Michigan State University researchers have identified a surprising level of metabolic redundancy in Staphylococcus aureus, a common pathogen, possibly paving the way for novel antibiotic advancement.
In the ongoing battle against antibiotic resistance, scientists are constantly seeking new vulnerabilities in bacteria. A team at Michigan State University (MSU), led by MGI doctoral graduate Dr. Thomas Burtchett and Associate Professor Neal Hammer, has made a significant revelation that could reshape our approach to combating bacterial infections. Their research, published in mBio, reveals a remarkable redundancy in how Staphylococcus aureus (staph) produces essential molecules called isoprenoids.
Isoprenoids are vital building blocks for bacteria, playing crucial roles in everything from cell membrane structure to energy production. For years, researchers believed that a specific enzyme, IspA, was the primary workhorse for producing short-chain isoprenoids in staph. Though, when Burtchett and Hammer investigated what happened when IspA was absent, they found something unexpected: the bacteria remained viable.
“One of the conclusions is that there is an amazing level of redundancy in isoprenoid synthesis in S. aureus,” said Burtchett. “This has never been demonstrated before.”
The Role of HepT and the Search for a Third Player
This observation led Burtchett and Hammer to hypothesize that another enzyme might be stepping in to compensate for the loss of IspA. Their attention turned to HepT, an enzyme belonging to the same class as IspA and also present in staph. Their examination revealed that HepT was involved in previously unrecognized pathways, including the synthesis of a molecule essential for bacterial respiration.”with this new details, they concluded that HepT must be compensating for the missing IspA by producing the short-chain isoprenoids,” the university stated.
To confirm their theory, the team, along with MGI doctoral student Jessica Lysne, engineered a double mutant lacking both ARI (the gene encoding IspA) and hepT. To their surprise, even with both IspA and HepT removed, the staph bacteria were still alive. This finding strongly suggests the existence of a third, as-yet-unidentified enzyme that is also capable of producing these critical short-chain isoprenoids.
Implications for Antibiotic Development
The implications of this discovery for antibiotic development are profound. Antibiotic resistance is a growing global health crisis, with bacteria evolving to evade existing drugs.by identifying previously untargeted metabolic pathways, researchers can develop new antibiotics that bacteria have not yet developed defenses against.
“If it’s new, there’s probably not existing resistance to it,” Burtchett explained. “It might be more challenging to gain resistance to it, and you can get more use out of that antibiotic.”
The high degree of conservation of isoprenoid synthesis pathways across bacterial species means that these findings could have broad applications, potentially leading to new treatments for infections caused by other pathogens like E. coli and Pseudomonas.
The future of Therapeutic Intervention
The MSU team is excited about the future research directions opened by their findings. Identifying the elusive third enzyme is now a key priority.
“Dr. Burtchett’s findings open exploration into several new areas of research, the most relevant being the identity of the third short-chain isoprenoid synthesis enzymes,” said hammer.”Identifying this enzyme will provide new targets for therapeutic intervention.”
This groundbreaking research highlights the intricate and frequently enough hidden complexities of bacterial metabolism, offering a beacon of hope in the urgent quest for new weapons against drug-resistant infections.
Source: Michigan State university
Journal Reference: Burtchett, T.A.,et al. (2025). A redundant isoprenoid biosynthetic pathway supports Staphylococcus aureus metabolic versatility. mBio*. doi.org/10.1128/mbio.00353-25